Sanofi-Aventis/Altana's Asthma Therapy Alvesco Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says the review decision came directly from ODE II rather than the Division of Pulmonary & Allergy Drug Products. Aventis had touted Alvesco as one of six product launches that would drive organic growth during its attempts to fend off Sanofi's merger bid.